 Shares of Trillium Therapeutics Inc. TRIL, 3.92 nearly tripled in premarket trading Monday, skyrocketing 189.3, after the immuno-oncology company announced an agreement to be acquired by Pfizer Inc. PFE, -0.16 in a cash deal valued 2.26 billion. Under terms of the agreement, Pfizer will pay 18.50 for each Trillium share it doesnt already own, which is 203.8 above Fridays closing price of 6.09. 